Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240162 · ClinicalTrials.gov registry record · Phase 2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00240162 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 21 participants.
The verdict
NCT00240162, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein levels are \< 5 g/dL following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT).
Interventions
- DRUG PTK787/ZK 222584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240162
The ClinicalTrials.gov registry entry for NCT00240162 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTK787/ZK 222584 is the first listed.
NCT00240162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240162 about?
NCT00240162 is a clinical study titled "PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma". The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein levels are \< 5 g/dL following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT).
What is the current status of trial NCT00240162?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2005-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00240162?
The interventions under investigation include: PTK787/ZK 222584 (DRUG).
Who is sponsoring clinical trial NCT00240162?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.